A couple of old slides used to show how the 4 week overlap will help with the new mono pivotal trial. Here with 525mg, 70% of the failures of the first 10 weeks occurred within this new overlap period. Adding the CCR5 density test should eliminate some of the later failures. I'm looking forward to seeing how the primary endpoint is defined around the induction/maintenance phases.